Louis Garguilo

ARTICLES BY LOUIS

  • Solutions Needed For Automated And Analytical Services In Fill Finish
    Solutions Needed For Automated And Analytical Services In Fill Finish

    For fill finish services at CDMOs, two items high on biopharma executives’ wish list are increased analytical and testing capabilities, and automation to replace manual product-line inspection. However, it appears to the CDMOs that customers are saying, ‘The onus is on you to figure it out … and pay it forward.” Is there a mutually acceptable solution?

  • JPMorgan Chase CEO Jamie Dimon And Outsourced Pharma Readers
    JPMorgan Chase CEO Jamie Dimon And Outsourced Pharma Readers

    Each year, Jamie Dimon’s annual letter to shareholders is considered required reading by folks on Wall Street and elsewhere. Dimon is Chairman and CEO of JP Morgan Chase, the largest of the big four American banks. Reading through his letter this year, I found three areas we might consider directly relevant to Outsourced Pharma readers. 

  • CDMOs Respond: Paying For A New Fill Finish Paradigm
    CDMOs Respond: Paying For A New Fill Finish Paradigm

    As vivaciously as our board members responded to a question regarding their biggest challenges when contracting fill finish services, CDMOs have now reacted in kind. The reactions come from around the world, including four CEOs of CDMOs. One thing both sides agree: They are operating within an encompassing paradigm shift.

  • Challenges With Fill Finish Services Not Finished
    Challenges With Fill Finish Services Not Finished

    Ours is a responsive Editorial Advisory Board, but no question posed to them elicited the range and rate of response as this one:

  • Here’s An Idea: Let’s Build A High-Potency Generics Facility
    Here’s An Idea: Let’s Build A High-Potency Generics Facility

    In 2005, a couple of guys in Waterford, Ireland, got together and said: “There’s not enough high-potency, high-containment facilities in the world. Why not build one?” While they were at it, they also decided to focus a new facility on developing and producing innovative generics. What could be so easy?

  • Non-Solutions For Drug Prices: CDMOs Complicit Or Exemplar?
    Non-Solutions For Drug Prices: CDMOs Complicit Or Exemplar?

    When are “solutions” not solutions? When they don’t solve the problems for which they are intended. In part two of our pre-publication review of “Drugs, Money, And Secret Handshakes,” we start with the incongruous idea that raising prices will help lower prices. And we analyze the role of outsourcing.

  • Include CDMOs In “Drugs, Money And Secret Handshakes”
    Include CDMOs In “Drugs, Money And Secret Handshakes”

    “Drugs, Money, and Secret Handshakes” is one hundred power-packed pages from author Robin Feldman, the Arthur J. Goldberg Distinguished Professor of Law at the University of California Hastings. Feldman provided Outsourced Pharma  a pre-publication copy of the book. Here’s part one of my review.

  • “Tobacco Road” Brings Biopharma-CDMOs Together
    “Tobacco Road” Brings Biopharma-CDMOs Together

    Effective government/private-enterprise partnerships; biopharma and CDMOs working collaboratively and internationally on innovative plant-made pharmaceuticals; the advancement of biopharma-CDMO business models. And we can partly thank tobacco plants. Who would have thought?

  • A High-Potency Biopharma-CDMO Model Working … As Planned
    A High-Potency Biopharma-CDMO Model Working … As Planned

    Tough to admit – after all, editors are supposed to be good at editing – but I didn’t know where to start this narrative. (And don’t murmur, “Try at the beginning,” because you’d be reading ‘till Christmas.)

  • Divine Outsourcing Model For Biotechs
    Divine Outsourcing Model For Biotechs

    Imagine you are a virtual biopharma developing a plant-based biopharmaceutical, and you contact the CDMO with the most experience in the field. The CDMO offers its technology/knowhow, to help file an IND, and supply the clinical material and launch quantities. Then it'll assist you in building your own commercial facility in your home market. Sound too good to be true?

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.